Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 8;5(1):e250028.
doi: 10.1530/EO-25-0028. eCollection 2025 Jan.

Survival and prognostic differences between appendiceal NETs and goblet cell adenocarcinomas

Kim Dijke  1   2 , José van den Berg  3 , Koert F D Kuhlmann  4 , Sonja Levy  5 , Gerlof D Valk  2 , Margot E T Tesselaar  1   5
Affiliations

Survival and prognostic differences between appendiceal NETs and goblet cell adenocarcinomas

Kim Dijke et al. Endocr Oncol. .

Abstract

Objective: Patients with appendiceal neuroendocrine tumours (aNETs) have an excellent prognosis. Appendiceal goblet cell adenocarcinomas (aGCAs), formerly called goblet carcinoid, show overlapping features with aNETs. Many discrepancies exist between studies regarding prognostication of patients with aNETs. In this study, we aim to identify differences in disease course between aNETs and aGCAs to explain inconsistencies in the literature and identify variables influencing recurrence and survival.

Methods: Patients with aNET or aGCA diagnosed between 2000 and 2019 were included. Kaplan-Meier curves were performed in patients with aNET and aGCA independently and in a combined group covering both aNETs and aGCAs to assess progression-free survival (PFS) and disease-specific survival (DSS). Cox regression was used to identify variables influencing PFS and DSS.

Results: In total, 122 patients were included: 92 with aNET and 30 with aGCA. Five- and 10-year PFS rates in patients with aNET were both 98%, whereas in patients with aGCA, this was 57% and 30%, respectively. The 5- and 10-year DSS rates for aNETs were 100 and 96%, and for aGCAs, this was 77 and 58%. In the combined group, 5- and 10-year DSS were 92 and 84%, and the presence of peritoneal metastases showed worse DSS (P < 0.001). WHO grade 3 was associated with poorer PFS (HR 18.68, 95% CI (2.24-155.59), P = 0.007) and DSS (HR = 10.21, 95% CI (1.23-85.08), P = 0.032) in aGCAs.

Conclusion: aNETs and aGCAs are different entities with a distinct prognosis. Differences in DSS between aNETs and aGCAs indicate previous studies misclassified aggressive tumours as aNETs, which addresses the importance of accurate tumour registration and reckoning with changes in nomenclature.

Keywords: appendiceal neoplasms; carcinoid tumour; goblet cell adenocarcinoma; neuroendocrine tumour; neuroendocrine tumours of the appendix.

PubMed Disclaimer

Conflict of interest statement

There is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Figures

Figure 1
Figure 1
Kaplan–Meier curve for PFS in patients with aNET and aGCA.
Figure 2
Figure 2
Kaplan–Meier curve for DSS in patients with aNET and aGCA.
Figure 3
Figure 3
Kaplan–Meier curve for DSS in patients with and without peritoneal metastasis (M1b).
Figure 4
Figure 4
Kaplan–Meier curve for DSS in patients with aGCA subdivided based on WHO grade.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Alabraba E, Pritchard DM, Griffin R, et al. 2021a. Appendiceal goblet cell carcinomas have poor survival despite completion surgery. Endocrine 73 734–744. ( 10.1007/s12020-021-02727-9) - DOI - PubMed
    1. Alabraba E, Pritchard DM, Griffin R, et al. 2021b. The impact of lymph node metastases and right hemicolectomy on outcomes in appendiceal neuroendocrine tumours (aNETs). Eur J Surg Oncol 47 1332–1338. ( 10.1016/j.ejso.2020.09.012) - DOI - PubMed
    1. Assarzadegan N & Montgomery E. 2021. What is new in the 2019 World Health Organization (WHO) classification of tumors of the digestive system: review of selected updates on neuroendocrine neoplasms, appendiceal tumors, and molecular testing. Arch Pathol Lab Med 145 664–677. ( 10.5858/arpa.2019-0665-ra) - DOI - PMC - PubMed
    1. Bayhan Z, Yildiz YA, Akdeniz Y, et al. 2020. Appendix neuroendocrine tumor: retrospective analysis of 4026 appendectomy patients in a single center. Emerg Med Int 2020 4030527. ( 10.1155/2020/4030527) - DOI - PMC - PubMed
    1. Bell PD & Pai RK. 2022. Goblet cell adenocarcinoma of the appendix: an update and practical approach to diagnosis and grading. Hum Pathol 132 183–196. ( 10.1016/j.humpath.2022.06.002) - DOI - PubMed

LinkOut - more resources